Distinctions Without a Difference?
Psychiatry has long been preoccupied with distinguishing one psychiatric disorder from another. Lacking objective, biological measures, experts have clustered symptoms into syndromes and then constructed them into psychiatric disorders memorialized as numerous nosologic entities. Although many originally hoped that isolating specific syndromes in this way would assist in identifying their pathophysiology, the road from disease to gene and neurobiology in psychiatry has not been smooth.
In fact, it now appears that genes regulate brain circuits that control symptoms across many diagnostic entities (Table 1 1,2 ), showing no genetic or neurobiological distinctions between disorders with the same symptoms.
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Therapeutic Agents Burn Through Nosologic Firewalls
At the same time that psychiatric nosology has been preoccupied with diagnostic distinctions that are turning out to have no unique biological or genetic differences, psychopharmacology has been preoccupied with distinguishing one class of drugs from another, e.g., calling them antidepressants, anxiolytics, antipsychotics, mood stabilizers, and the like. The original notion of aligning drug classification with diagnostic syndromes seemed rational. What has transpired, however, is that psychopharmacologic treatments are now recognized to work in symptoms that cross many diagnostic entities, resulting in drugs classified for one disorder able to treat the same symptoms in another disorder. 4 Thus, an even more important paradigm shift is occurring in psychopharmacology. Agents treat the same symptom in different disorders and also treat many different symptoms in sometimes unrelated diagnostic conditions (Table 2) . 5, 6 This surprisingly broad therapeutic utility of psychotropic drugs is burning through nosologic firewalls. Since the neurotransmitters that a specific drug modifies are active in several circuits mediating several different symptoms, a single drug acting on a given neurotransmitter can have simultaneous therapeutic actions in different circuits. A further elaboration of this model is that psychiatric disorders manifest themselves as a portfolio of symptoms, implying a portfolio of malfunctioning circuits. The neurotransmitters in these circuits are being clarified empirically as are the therapeutic actions of psychopharmacologic agents that can boost or block these neurotransmitters and thus expand their portfolio of therapeutic actions to symptom reduction in many disorders.
Nodes in the Nexus
Functional neuroimaging is beginning to map out the brain's reactions to emotions and cognitions in both health and disease. [1] [2] [3] Key to this concept is a nexus, or network of neurons involved in any given symptom generation, with key brain areas specializing in specific functions. The entire nexus can be associated with changes in neuronal firing patterns at various Targeting Symptoms in Circuits to Attain Remission While neurobiologists are sorting out which circuits mediate which symptoms, their strategy can be empirically applied immediately by the neurobiologically informed psychopharmacologist. Thus, patients can have a symptom inventory taken at the time of evaluation. Treatments can be chosen to alleviate these symptoms from the known and best-characterized actions of drugs. However, at this point things get interesting, because in most cases, patients are not completely devoid of all symptoms after their initial treatment. The usual outcome is elimination of some symptoms, but often only partial relief of other symptoms, and no relief of still more symptoms.
A practical approach to treat these unresolved symptoms is to conceptualize which circuits might be mediating them, which neurotransmitters have been targeted by the current treatment, and which neurotransmitters must now be targeted to eliminate residual symptoms and attain complete remission. Thus, the common situation of antidepressants improving mood but not eliminating fatigue and somatic symptoms can lead to augmentation with a second agent targeted at fatigue in particular. Likewise, the situation of antipsychotics improving positive but not cognitive symptoms in schizophrenia can lead to long-term use of a monotherapy, in order to maximize the chances of the usually delayed procognitive actions of an atypical antipsychotic, rather than changing to another agent too early. The point is to have a proactive, neurobiologically based treatment strategy and to try and try again to target every symptom in every circuit by using rational drug selections and combinations from the therapeutic arsenal at hand. This approach could lead to better individualized treatment and patient outcomes. ◆
